Japan Next-Generation Sequencing (NGS) Services Market (2017-2022)
The Japan Next-Generation Sequencing (NGS) Services Market was valued at $33.3 Million in 2017 and projected to reach to $85.1 Million by 2022, representing a compound annual growth rate of 20.6%. Japan's NGS services market is positioned for sustained growth through 2022 and beyond, supported by the country's commitment to precision medicine and genomic research excellence.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Japan Next-Generation Sequencing (NGS) Services Market Trends and Insights
- In 2017, Japan's NGS services market was valued at $33.3 million, establishing a strong foundation for accelerated growth driven by increased genomic research investments and clinical applications.
- By 2022, Japan's market is forecast to reach $85.1 million, representing a compound annual growth rate of 20.6% and underscoring the nation's commitment to genomic innovation. Japan's NGS services sector benefits from substantial government support for life sciences research, rising prevalence of genetic disorders, and expanding pharmaceutical and biotechnology sectors.
- Japan's aging population and emphasis on personalized healthcare solutions have catalyzed demand for advanced sequencing technologies across diagnostic, research, and therapeutic applications.
- The trajectory from $33.3 million in 2017 to $85.1 million in 2022 positions Japan as a significant contributor to the Asia Pacific NGS services landscape, with continued momentum expected as clinical adoption deepens..
Key Market Statistics
- CAGR (2017-2022) 20.6% CAGR
- Market Size, 2017 ~USD 33.3 Million
- Forecast, 2022 ~USD 85.1 Million
- Country Japan
Japan Next-Generation Sequencing (NGS) Services Market Overview
Rapid Market Expansion :
Japan's NGS services market grew from $33.3 million in 2017 to $85.1 million in 2022, representing a 20.6% CAGR and demonstrating strong market momentum driven by precision medicine adoption.
Advanced Healthcare Infrastructure :
Japan's sophisticated healthcare system and high healthcare spending per capita create an ideal environment for NGS service adoption, with strong institutional support for genomic research initiatives.
Genomic Research Investment :
Increased government and private sector investments in genomic research programs have accelerated NGS service utilization across Japanese research institutions and clinical laboratories.
Clinical Application Growth :
Expanding clinical applications of NGS in oncology, rare disease diagnosis, and personalized medicine are driving demand among Japanese hospitals and diagnostic centers.
Japan Next-Generation Sequencing (NGS) Services Market Dynamics
- The market's 20.6% CAGR reflects increasing adoption among clinical laboratories, research institutions, and pharmaceutical companies seeking advanced sequencing capabilities.
- Japan's aging population and prevalence of genetic disorders create strong demand drivers for NGS-based diagnostics and treatment planning. Future growth will be catalyzed by technological advancements, declining sequencing costs, and expanded reimbursement coverage for NGS-based tests.
- Japanese healthcare providers are increasingly integrating NGS into standard diagnostic protocols, particularly in oncology and rare disease management.
- Continued investment in genomic infrastructure and skilled workforce development will solidify Japan's position as a leading NGS services market in Asia-Pacific..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Danaher Corporation
Key Takeaways
- Japan's NGS services market grew from $33.3 million in 2017 to a forecasted $85.1 million in 2022, representing a 20.6% CAGR.
- Japan's advanced healthcare infrastructure and government support for genomic research drive sustained market expansion and clinical adoption.
- Japan's aging population and focus on personalized medicine create strong demand for NGS-based diagnostic and therapeutic applications.
- Japan's position within Asia Pacific positions the country as a key growth hub for next-generation sequencing service providers.
Next-Generation Sequencing (NGS) Services Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2017 |
| Fastest Growing Segment | AGRICULTURE & ANIMAL RESEARCH (Application) |
| Forecast Period | 2017–2022 |
| Growth Rate | CAGR of 21% from 2017 to 2022 |
| Largest Segment | DIAGNOSTICS (Application) |
| Market Size Base Year (Billions) | ~USD 1.06 (2017) |
| Revenue Forecast (Billions) | ~USD 2.748 (2022) |
| Segments Covered | Type, Application, End User, Technology |
Japan Next-Generation Sequencing (NGS) Services Market Report Segmentation
4 segment dimensions are covered across the global market.
By Type
- Chip-Seq
- De Novo Sequencing
- Exome Sequencing
- Methyl-Seq
- Other Ngs Services
- Other Services
- Rna-Seq
- Targeted Sequencing/Custom Gene Panels
- Targeted Sequencing/Gene Panels
- Whole-Genome Sequencing
By Application
- Agriculture & Animal Research
- Biomarker Discovery
- Diagnostics
- Drug Discovery
- Infectious Diseases
- Oncology
- Other Applications
- Other Applications*
- Other Diagnostic Applications
- Rare Genetic Disorders
- Reproductive Health
By End User
- Academic & Government
- Academic & Government Institutes And Research Centers
- Hospitals & Clinics
- Other End Users
- Other End Users*
- Pharmaceutical & Biotechnology Companies
By Technology
- Ion Semiconductor Sequencing
- Nanopore Sequencing
- Sequencing By Synthesis
- Single-Molecule Real-Time Sequencing
Target Audience
- NGS Service Providers : Sequencing companies and diagnostic laboratories need Japan-specific market data to assess market potential, competitive positioning, and expansion strategies in this high-growth Asian market.
- Healthcare Investors : Private equity and venture capital firms require detailed Japan NGS market analysis to evaluate investment opportunities, growth trajectories, and exit potential in the precision medicine sector.
- Pharmaceutical Companies : Drug developers and biotech firms need insights into Japan's NGS adoption rates and clinical applications to inform companion diagnostic strategies and precision medicine initiatives.
- Hospital & Laboratory Administrators : Japanese healthcare facility leaders require market benchmarking data and adoption trends to make informed decisions about NGS service implementation and technology investments.
- Market Research & Consulting Firms : Research organizations need comprehensive Japan NGS market data to support client advisory services, competitive analysis, and strategic planning in the healthcare genomics sector.
Key Companies in the Japan Next-Generation Sequencing (NGS) Services Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ILLUMINA, INC. | United States | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| PERKINELMER, INC. | United States | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| EUROFINS SCIENTIFIC SE | Luxembourg | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| MACROGEN, INC. | South Korea | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| QIAGEN N.V. | Netherlands | Public Company | Targeted sequencing services (panels, amplicon, gene panels),RNA-Seq services,Exome and de novo sequencing services, |
| DNA LINK, INC. | South Korea | Public Company | Whole genome & De Novo sequencing services,Whole exome & targeted sequencing services,Transcriptome & single-cell RNA sequencing, |
| TAKARA BIO INC. (PART OF TAKARA HOLDING COMPANY INC.) | Japan | ||
| NOVOGENE CORPORATION | China | Public Company | Whole genome and targeted sequencing services (incl. human/animal/plant/microbial WGS and targeted panels),Transcriptomics and single-cell sequencing (mRNA, lncRNA, small RNA, single-cell, spatial),De novo, metagenomics, and microbiome sequencing, |
| PERSONALIS, INC. | United States | Public Company | Oncology MRD and monitoring (NeXT Personal, NeXT Personal Dx),Comprehensive tumor profiling (ImmunoID NeXT, NeXT Dx),Population and research sequencing (WES/WGS services), |
ILLUMINA, INC.
Illumina, Inc. is a public company founded in 1998 and headquartered in the United States with 8,625 employees. The company is a leader in DNA sequencing and genetic analysis technologies.
PERKINELMER, INC.
PerkinElmer, Inc. is a public company founded in 1937 and based in the United States with 11,000 employees. The company provides diagnostic and research solutions across life sciences and environmental testing.
EUROFINS SCIENTIFIC SE
Eurofins Scientific SE is a public company founded in 1987 and headquartered in Luxembourg with 65,694 employees. The company operates a network of laboratories providing testing and analytical services across multiple industries.
MACROGEN, INC.
Macrogen, Inc. is a public company founded in 2000 and based in South Korea with 293 employees. The company provides genomic research services including DNA sequencing and analysis.
QIAGEN N.V.
QIAGEN N.V. is a public company founded in 1984 and headquartered in the Netherlands with 5,500 employees. The company develops and manufactures molecular diagnostics and life sciences tools.
DNA LINK, INC.
DNA Link, Inc. is a public company founded in 2000 and based in South Korea with 84 employees. The company offers genomic analysis and genetic testing services.
TAKARA BIO INC. (PART OF TAKARA HOLDING COMPANY INC.)
Takara Bio Inc. is a company based in Japan and operates as part of Takara Holding Company Inc. The company specializes in biotechnology and life sciences research products.
NOVOGENE CORPORATION
Novogene Corporation is a public company founded in 2011 and based in China with 2,225 employees. The company provides genomic sequencing and bioinformatics analysis services.
PERSONALIS, INC.
Personalis, Inc. is a public company founded in 2011 and based in the United States with 260 employees. The company develops genomic testing and analysis solutions for precision medicine.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise market valuation data for Japan ($33.3M in 2017, $85.1M in 2022) with verified 20.6% CAGR to support investment decisions and business planning in the Japanese NGS sector.
- Competitive Landscape Intelligence : Understand Japan-specific market dynamics, key players, and competitive positioning to identify partnership opportunities and market entry strategies tailored to the Japanese healthcare ecosystem.
- Clinical Adoption Insights : Access detailed analysis of NGS adoption rates across Japanese hospitals, diagnostic centers, and research institutions to benchmark performance and identify high-growth clinical segments.
- Regulatory & Reimbursement Analysis : Gain comprehensive understanding of Japan's regulatory framework, reimbursement policies, and healthcare system requirements specific to NGS services for compliant market expansion.
- Strategic Growth Opportunities : Identify emerging opportunities in precision oncology, rare disease diagnosis, and personalized medicine within Japan's advanced healthcare market to drive revenue growth and market share expansion.
Frequently asked questions
What was Japan's NGS services market size in 2017?
Japan's NGS services market was valued at $33.3 million in 2017, serving as the baseline for subsequent growth projections.
What is the forecast for Japan's NGS services market in 2022?
Japan's NGS services market is forecast to reach $85.1 million by 2022, reflecting strong market momentum and clinical adoption.
What is the CAGR for Japan's NGS services market?
Japan's NGS services market is projected to grow at a compound annual growth rate of 20.6% between 2017 and 2022.
What factors are driving growth in Japan's NGS services market?
Japan's NGS market growth is driven by government support for genomic research, an aging population, rising genetic disorder prevalence, and increased adoption of personalized medicine approaches.
How does Japan's NGS market compare to the global market?
Japan's NGS services market CAGR of 20.6% aligns closely with the global CAGR of 21%, demonstrating Japan's strong participation in the worldwide genomic services expansion.
RESEARCH METHODOLOGY
Get the Full Next-Generation Sequencing (NGS) Services Market Report
Full forecast, segment splits, and company analysis for all Next-Generation Sequencing (NGS) Services Market.
- Canada Next-Generation Sequencing (NGS) Services Market
- Germany Next-Generation Sequencing (NGS) Services Market
- France Next-Generation Sequencing (NGS) Services Market
- China Next-Generation Sequencing (NGS) Services Market
- India Next-Generation Sequencing (NGS) Services Market
- U.S. Next-Generation Sequencing (NGS) Services Market
- Roe Next-Generation Sequencing (NGS) Services Market
- U.K. Next-Generation Sequencing (NGS) Services Market
- Roapac Next-Generation Sequencing (NGS) Services Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
